Skip to main content
. 2015 Aug 18;53(9):2956–2960. doi: 10.1128/JCM.01317-15

TABLE 1.

Results of FilmArray BioThreat E panel and qRT-PCR testing using serial dilutions of inactivated Zaire ebolavirus at known titers in whole blooda

Virus titer (TCID50/ml) NP2 results
VP40 results
FilmArray results
Test 1 Test 2 Test 1 Test 2 Test 1 Test 2
40,000,000 Positive (CT = 20) Positive (CT = 20) Positive (CT = 18) Positive (CT = 18) Detected Detected
4,000,000 Positive (CT = 23) Positive (CT = 23) Positive (CT = 22) Positive (CT = 22) Detected Detected
400,000 Positive (CT = 26) Positive (CT = 26) Positive (CT = 25) Positive (CT = 25) Detected Detected
40,000 Positive (CT = 30) Positive (CT = 30) Positive (CT = 28) Positive (CT = 28) Detected Detected
4,000 Positive (CT = 33) Positive (CT = 33) Positive (CT = 32) Positive (CT = 32) Detected Detected
400 Positive (CT = 37) Positive (CT = 35) Positive (CT = 34) Positive (CT = 34) Detected Detected
40 Negative Negative Negative Positive (CT = 37) Not detected Not detected
0 Negative Negative Negative Negative Not detected Not detected
a

Zaire ebolavirus (strain 812592) stock at a known titer of 4 × 108 TCID50/ml was inactivated by gamma irradiation prior to testing. EUA-approved NP2 and VP40 qRT-PCR assays and FilmArray BT-E panel testing were performed in duplicate, using 10-fold serial dilutions of inactivated virus in whole blood, at the CDC.